Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk | ||
By: PR Newswire Association LLC. - 28 Aug 2015 | Back to overview list |
|
DUBLIN, Aug. 28, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/rktnl9/investigation) has announced the addition of the "Investigation Report on China's Insulin Aspart Market, 2010-2019" report to their offering. Developed by Novo Nordisk, insulin aspart (under the trade name of Novolog) is an important drug for the treatment of diabetes. Compared with human insulin, insulin aspart, as a fast- acting insulin analog, starts working fast and reports higher peak of glucose- lowering action and lower risk of hypoglycemia. Ever since insulin aspart for injection was approved to enter China in 2012, it has been in the market for over a decade. Although the market is currently dominated by product of Novo Nordisk, some local enterprises are trying to make generic drugs. China Food and Drug Administration (CFDA) announced on its website on Jun.3, 2014 that Hisun's application to produce the APIs of insulin aspart and insulin aspart for injection through recombinant DNA technology has been accepted. Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net SOURCE Research and Markets |
||
|
||
Copyright 2015 PR Newswire Association LLC. | Back to overview list |